About Us
Executive Director, Chief Executive Officer: Mr. Eric Tse
-
- Executive Director, Chief Executive Officer: Mr. Eric Tse
- Mr. Eric Tse was appointed as an Executive Director of Sino Biopharmaceutical Limited in 2019, the Chairman of Chia Tai Tianqing Pharmaceutical Group Co., Ltd. in 2020, and the Chief Executive Officer of Sino Biopharmaceutical Limited and Chairman of Beijing Tide Pharmaceutical Co., Ltd. in 2022. He holds a Bachelor degree in Economics from the Wharton School of the University of Pennsylvania, a Master's degree in Management and Global Leadership from Schwarzman College, Tsinghua University, and is a Ph.D. candidate in Social and Administrative Pharmacy at China Pharmaceutical University. He was awarded the "Top 10 Outstanding Chinese American Youth" and the "Advanced Individual of the Outstanding Contribution to Manufacture in Jiangsu Award".
Mr. Eric Tse is currently a member of the Beijing Municipal Committee of the CPPCC, a member of All-China Youth Federation, a Vice Chairman of the 12th Committee of the Shaanxi Youth Federation, a member of the 7th Election Committee of the Hong Kong SAR, a vice president of the Youth Federation of Hong Kong Political Consultative Conference, a member of the Digital Economy Committee of the APEC China Business Council, a member of the Presidium of Global Shapers under the World Economic Forum, a Vice Chairman of the Science and Technology Innovation Committee of the Belt and Road General Chamber of Commerce, a member of the Y.Elites Association, and an Executive Vice President of the Jiangsu Overseas Chinese Entrepreneurs Association.
Since taking over as Chief Executive Officer of Sino Biopharm, Mr. Tse has focused on the four main strategies of "organizational integration, comprehensive innovation, globalization, and digitalization". He leads the daily operations of the group, advances major decisions on corporate strategy, personnel appointments, investment and integration. Hr alsocomprehensively manages the Group's subsidiary companies. builds a professional management team,further enhances organizational efficiency, drives innovative business, connects external collaborations, and advances the Group's global innovation process, aiming to establish a Chinese international innovative pharmaceutical company. Under the leadership of Mr. Tse, the company is commited to the path of innovation and transformation, and building long-term core competitive advantages through comprehensive innovation. Sino Biopharm and its subsidiaries, such as Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Beijing Tide Pharmaceutical Co., Ltd., uphold the mission of " Enhancing Life Quality, Upholding Life Dignity". With a focus on societal clinical medication needs, they focus on the four major areas of oncology, liver diseases, respiratory, and surgery/analgesic. They advance internal innovation and business development in parallel, cultivate a new innovation ecosystem, develop world-leading innovative R&D capabilities, enhance the Group's core competitiveness with new quality productive forces, and continuously achieve outstanding accomplishments and innovative breakthroughs. The proportion of innovative drug R&D investment at Sino Biopharm has increased to 77% of total R&D investment. Currently, with more than 70 innovative drugs in the pipeline, with a forward-looking layout of multiple new targets, new platforms, and new technologies with blockbuster potential. In the next three years, more than 10 innovative drugs will be launched to serve patients. Leveraging the strong platform of Sino Biopharm, its subsidiaries Chia Tai Tianqing and Beijing Tide Pharmaceutical have developed steadily. For many consecutive years, they have been selected for authoritative industry lists such as the Top 100 Pharmaceutical Companies in China and the Best Industrial Enterprises for Pharmaceutical R&D Pipelines in China. They have undertaken more than 80 national and provincial science and technology projects and have received honors such as the "China Patent Gold Award" and the "National Science and Technology Progress Award".
While dedicated to corporate management, Mr. Eric Tse is passionate about and actively involved in youth work in Hong Kong and Chinese mainland. He continuously speaks up via the Hong Kong media on important topics such as Hong Kong's integration into the national development strategy, the steady and long-term implementation of "One Country, Two Systems", and promoting Hong Kong's transition "from governance to prosperity", contributing to the long-term prosperity, stability, and continued brilliance of Hong Kong.
*Portrait rights belong to the individual. Unauthorized use is prohibited.
-
Sino Biopharm Appears at International Biopharma Industry Week Shanghai 2025, Eric Tse: Deeply Rooting and Broadly Connecting by Leveraging Shanghai as a Global Hub 2025.10
From October 13 to 17, the International Biopharma Industry Week Shanghai 2025 was held in Shanghai, marking the fifth consecutive year that Shanghai has hosted this global platform.View > -
Sino Biopharm Donates HK$10 Million in Cash and Medicine for Emergency Relief of Tai Po Fire in Hong Kong 2025.11
On November 26, a sudden fire broke out at Wang Fuk Court in Tai Po District, New Territories, Hong Kong, drawing concern from across the nation.View > -
Ta Kung Pao | Net Profit Doubles with 27.2% Surge in Innovative Product Revenue - Sino Biopharm Announces 2025 Interim Results 2025.08
Driven by the dual forces of policy support and innovation, the domestic pharmaceutical industry is accelerating its recovery. On August 18, Hong Kong-listed leading pharmaceutical company Sino Biopharm (01177.HK) announced its 2025 semi-annual results. In the first half of the year, the company achieved revenue of RMB 17.57 billion and net profit attributable to owners of the parent of RMB 3.39 billion, representing year-on-year increases of 10.7% and 140.2%, respectively, marking three consecutive reporting periods of stable double-digit growth.View > -
Sino Biopharm 2024 Full-Year Results Announcement: Double-Digit Growth in Both Revenue and Net Profit, Innovative Product Revenue Exceeds 12 Billion, a New High 2025.03
On March 20, Sino Biopharm (HK.01177) released its 2024 annual results report, delivering an impressive "double-digit growth" across two key metrics: full-year revenue for 2024 reached RMB 28.87 billion, a year-on-year increase of 10.2%, hitting a record high; adjusted net profit attributable to owners of the parent company reached RMB 3.46 billion, a year-on-year increase of 33.5%.View > -
From "Leading Innovation" to "Investing in Innovation", Sino Biopharm Leading (Shanghai) Private Investment Fund Unveiled and Established 2025.04
On April 22, the Sino Biopharm Leading (Shanghai) Private Investment Fund (hereinafter referred to as the "Sino Biopharm Leading Fund") was unveiled and established in the Pudong New Area. This is a major initiative by Sino Biopharm to invest in, empower, and cultivate innovation, following its commitment to comprehensive innovation and the achievement of leapfrog innovative development.View > -
Mr. Eric Tse Attends Summer Davos Forum and Advocates for AI-Driven Innovation to Fast-Track New Drug R&D 2025.06
On June 24, the 16th Annual Meeting of the New Champions 2025 of the World Economic Forum (also known as the Summer Davos Forum) opened in Tianjin.View > -
Mr. Eric Tse at the Summer Davos Forum: Deepening Industry-Wide Collaborative Innovation to Drive the Leapfrog Advancement of Biomedicine 2025.06
On June 25, the "Summer Davos Forum" 2025 was held in Tianjin. Premier Li Qiang of the State Council attended the opening ceremony and a symposium with representatives from the business community.View > -
Senior Chairman of Charoen Pokphand Group Mr. Dhanin Chearavanont Attended the 80th Anniversary of the Victory in the Chinese People's War of Resistance, Leaders of CP Pharmaceutical Group Were Invited to Observe the Ceremony 2025.09
On the morning of September 3, a grand ceremony commemorating the 80th anniversary of the victory in the Chinese People's War of Resistance Against Japanese Aggression and the World Anti-Fascist War was held in Tiananmen Square, Beijing.View > -
President of The University of Hong Kong Zhang Xiang and Delegation Visited Chia Tai Tianqing to Explore New Paths for Industry-Academia-Research and Cross-Disciplinary Collaboration 2025.09
On September 6, Zhang Xiang, President of The University of Hong Kong, led a delegation to visit Chia Tai Tianqing, a core enterprise of Sino Biopharm. The delegation included Vice President Lin Chen of The University of Hong Kong and renowned entrepreneurs such as Wang Jianguo, Chairman of Five Star Holdings; Fan Min, Co-founder of Ctrip.com; Wang Zhihan, Chairman of the Board of Goheal Group; and Yang Xiao, Chairman of Renhe Pharmacy Co., Ltd.View > -
Mr. Eric Tse Attended Investor Forum: China's Pharmaceutical Industry Enters a New Development Cycle, Driven by Innovation in R&D and Global Expansion 2025.09
On September 8, the Chief Executive Officer of Sino Biopharm (1177.HK) was invited to attend the 32nd CITIC CLSA Investors' Forum and delivered a speech titled "Sino Biopharm: A Leading Innovation-Driven Pharmaceutical Company," systematically elaborating on the company's achievements and plans in strategic transformation, R&D innovation, and global layout. This forum brought together global industry experts, corporate executives, and top analysts to discuss investment trends and industry dynamics.View >